Pudong, China
Structure Therapeutics develops life‐changing medicines for patients using advanced structure‐based and computational drug discovery technology. The company’s platform combines the latest advancements in visualization of molecular interactions, computational chemistry, and data integration to design orally available, superior small molecule medicines that overcome current limitations of biologic and peptide drugs. We are advancing a clinical‐stage pipeline of differentiated treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic, and pulmonary conditions.
Structure Therapeutics is led by an experienced group of international drug innovators and financed by top-tier global life sciences investors. The company has completed an initial public offering (IPO) in February of 2023. With offices in California and Shanghai, Structure Therapeutics has the benefit of being at the center of life science innovation in both the US and China and capitalizing on the strengths of each geographic location.
Position Summary
This role will be the Head of Metabolic Disease Biology, provide scientific leadership to metabolic disease biology and discovery pipeline, and closely work with the Head of Biology to contribute to the overall company discovery portfolio strategy. This role will build and lead Metabolic Disease Biology team, recruit talents, and use their experience and skills to lead preclinical programs for metabolic diseases. This role will closely collaborate with cross-functional teams to drive discovery programs.
Essential Duties and responsibilities
QUALIFICATIONS: